MLTX
Price
$11.20Alerts
Change
+$0.41 (+3.80%)
Updated
Nov 19, 12:22 PM (EDT)
Capitalization
981.28M
105 days until earnings call
Intraday BUY SELL Signals
RARE
Price
$17.62Alerts
Change
-$0.11 (-0.62%)
Updated
Nov 19, 11:59 AM (EDT)
Capitalization
1.52B
91 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MLTX vs RARE

MLTX vs RARE Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
MLTX vs. RARE commentary
Nov 19, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MLTX is a Hold and RARE is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for MLTX with price predictions
Nov 18, 2026

MLTX in downward trend: price expected to drop as it breaks its higher Bollinger Band on November 11, 2026

MLTX broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 51 similar instances where the stock broke above the upper band. In 47 of the 51 cases the stock fell afterwards. This puts the odds of success at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MLTX as a result. In 76 of 106 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.

The Moving Average Convergence Divergence Histogram (MACD) for MLTX turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 40 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 74%.

MLTX moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MLTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MLTX's RSI Oscillator exited the oversold zone, 12 of 15 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The 10-day moving average for MLTX crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 17 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.

Following a +16.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where MLTX advanced for three days, in 257 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

The Aroon Indicator entered an Uptrend today. In 162 of 181 cases where MLTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.292) is normal, around the industry mean (3.592). P/E Ratio (-3.003) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).

The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. MLTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MLTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for RARE with price predictions
Nov 18, 2026

RARE in upward trend: price rose above 50-day moving average on November 09, 2026

RARE moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend. In 35 of 39 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 65 cases where RARE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.

The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on RARE as a result. In 72 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.

The 10-day moving average for RARE crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.

Following a +11.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where RARE advanced for three days, in 221 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

The Aroon Indicator entered an Uptrend today. In 151 of 226 cases where RARE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 67%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RARE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

RARE broke above its upper Bollinger Band on November 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-5.228) is normal, around the industry mean (3.592). P/E Ratio (-2.647) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (1.809) is also within normal values, averaging (442.120).

The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. RARE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RARE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
MLTX vs RARE: Fundamental Ratings
MLTX
RARE
OUTLOOK RATING
1..100
8487
VALUATION
overvalued / fair valued / undervalued
1..100
38
Fair valued
15
Undervalued
PROFIT vs RISK RATING
1..100
97100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
6163
P/E GROWTH RATING
1..100
1311
SEASONALITY SCORE
1..100
8590

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RARE's Valuation (15) in the Biotechnology industry is in the same range as MLTX (38) in the null industry. This means that RARE’s stock grew similarly to MLTX’s over the last 12 months.

MLTX's Profit vs Risk Rating (97) in the null industry is in the same range as RARE (100) in the Biotechnology industry. This means that MLTX’s stock grew similarly to RARE’s over the last 12 months.

MLTX's SMR Rating (98) in the null industry is in the same range as RARE (100) in the Biotechnology industry. This means that MLTX’s stock grew similarly to RARE’s over the last 12 months.

MLTX's Price Growth Rating (61) in the null industry is in the same range as RARE (63) in the Biotechnology industry. This means that MLTX’s stock grew similarly to RARE’s over the last 12 months.

RARE's P/E Growth Rating (11) in the Biotechnology industry is in the same range as MLTX (13) in the null industry. This means that RARE’s stock grew similarly to MLTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MLTXRARE
RSI
ODDS (%)
Bullish Trend 1 day ago
80%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bearish Trend 1 day ago
72%
Bullish Trend 1 day ago
83%
MACD
ODDS (%)
Bearish Trend 1 day ago
74%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
75%
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
72%
Advances
ODDS (%)
Bullish Trend 11 days ago
84%
Bullish Trend 1 day ago
79%
Declines
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 4 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
86%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
67%
COMPARISON
Comparison
Nov 19, 2026
Stock price -- (MLTX: $10.79 vs. RARE: $17.73)
Brand notoriety: MLTX and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MLTX: 78% vs. RARE: 110%
Market capitalization -- MLTX: $981.28M vs. RARE: $1.52B
MLTX [@Biotechnology] is valued at $981.28M. RARE’s [@Biotechnology] market capitalization is $1.52B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MLTX’s FA Score shows that 1 FA rating(s) are green while RARE’s FA Score has 2 green FA rating(s).

  • MLTX’s FA Score: 1 green, 4 red.
  • RARE’s FA Score: 2 green, 3 red.
According to our system of comparison, both MLTX and RARE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MLTX’s TA Score shows that 5 TA indicator(s) are bullish while RARE’s TA Score has 6 bullish TA indicator(s).

  • MLTX’s TA Score: 5 bullish, 5 bearish.
  • RARE’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, RARE is a better buy in the short-term than MLTX.

Price Growth

MLTX (@Biotechnology) experienced а -20.13% price change this week, while RARE (@Biotechnology) price change was +6.17% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.44%. For the same industry, the average monthly price growth was -11.41%, and the average quarterly price growth was -23.91%.

Reported Earning Dates

MLTX is expected to report earnings on Mar 04, 2027.

RARE is expected to report earnings on Feb 18, 2027.

Industries' Descriptions

@Biotechnology (-4.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

RARE and

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been loosely correlated with MREO. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if RARE jumps, then MREO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
+6.17%
MREO - RARE
58%
Loosely correlated
+5.39%
VCYT - RARE
46%
Loosely correlated
+5.53%
APVO - RARE
39%
Loosely correlated
-3.25%
MLTX - RARE
37%
Loosely correlated
-4.09%
AMRN - RARE
36%
Loosely correlated
-0.09%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ANTX4.950.72
+17.02%
AN2 Therapeutics
LVS39.27-0.05
-0.13%
Las Vegas Sands Corp
TNGX21.89-0.22
-1.00%
Tango Therapeutics
LIQT0.21N/A
-1.91%
LiqTech International
PSEC1.27-0.08
-5.93%
Prospect Capital Corp